RaQualia Pharma Inc (4579):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】RaQualia Pharma Inc (4579) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C8096)・商品コード:DATA904C8096
・発行会社(調査会社):GlobalData
・発行日:2018年10月
・ページ数:36
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
RaQualia Pharma Inc (RaQualia) is a drug development company that discovers and develops pharmaceutical compounds. The company offers products such as anidulafungin, ziprasidone, dalbavancin, 5-HT2B antagonist, motilin receptor agonist, potassium-competitive acid blockerand 5-HT4 partial agonist. Its products are used in the treatment of gastroparesis, chronic constipation, neuropathic pain, anorexia associated cancer, chronic inflammatory pain, and others. RaQualia also offers licensing of intellectual properties for pharmaceutical compounds. Its research collaboration areas include development of analytical evaluation systems, search for lead compounds, implementation of biological testing, and development of research tools. The company partners with universities, public research institutions, pharmaceutical companies, bio-venture firms and contract research organizations. RaQualia is headquartered in Nagoya, Japan.

RaQualia Pharma Inc (4579) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RaQualia Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RaQualia Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
RaQualia Pharma to Form Joint Venture with ZTE Biotech 11
RaQualia Pharma Enters into Agreement with Takeda Pharma 12
Sihuan Pharma Enters into Agreement with RaQualia Pharma 13
RaQualia Pharma Enters into Research Agreement with XuanZhu Pharma 14
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 15
RaQualia Pharma Enters Into Research Agreement With Interprotein For PPI Inhibitor 16
RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 17
Licensing Agreements 18
NewBay Medical Enters into Licensing Agreement with AskAt 18
Maruho Enters into Licensing Agreement with RaQualia Pharma 19
AskAt Enters into Licensing Agreement with Arrys Therapeutics 20
Ningbo Tai Kang Medical Enters into Licensing Agreement with AskAt 21
RMX Pharma Enters into Licensing Agreement with AskAt 22
Syros Pharma Amends Licensing Agreement with TMRC 23
TMRC Enters Into Licensing Agreement with Ohara Pharmaceutical 24
AskAt Receives Intellectual Property from RaQualia Pharma 25
Equity Offering 26
RaQualia Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 26
RaQualia Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 27
RaQualia Pharma Inc – Key Competitors 28
RaQualia Pharma Inc – Key Employees 29
RaQualia Pharma Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Product News 31
07/19/2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China 31
07/09/2018: Takeda completes the evaluation of RaQualia’s compound 32
07/06/2018: RaQualia Announces Receipt of Milestone Payment from CJ HealthCare 33
Product Approvals 34
Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China 34
Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People’s Republic of China 35
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RaQualia Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RaQualia Pharma Inc, Deals By Therapy Area, 2012 to YTD 2018 8
RaQualia Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
RaQualia Pharma to Form Joint Venture with ZTE Biotech 11
RaQualia Pharma Enters into Agreement with Takeda Pharma 12
Sihuan Pharma Enters into Agreement with RaQualia Pharma 13
RaQualia Pharma Enters into Research Agreement with XuanZhu Pharma 14
RaQualia Pharma Enters Into Research Agreement With Asahi Kasei Pharma 15
RaQualia Pharma Enters Into Research Agreement With Interprotein For PPI Inhibitor 16
RaQualia Pharma Enters into Research Agreement with Ajinomoto Pharma 17
NewBay Medical Enters into Licensing Agreement with AskAt 18
Maruho Enters into Licensing Agreement with RaQualia Pharma 19
AskAt Enters into Licensing Agreement with Arrys Therapeutics 20
Ningbo Tai Kang Medical Enters into Licensing Agreement with AskAt 21
RMX Pharma Enters into Licensing Agreement with AskAt 22
Syros Pharma Amends Licensing Agreement with TMRC 23
TMRC Enters Into Licensing Agreement with Ohara Pharmaceutical 24
AskAt Receives Intellectual Property from RaQualia Pharma 25
RaQualia Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 26
RaQualia Pharma Raises Funds through Private Placement of Shares upon Exercise of Warrants 27
RaQualia Pharma Inc, Key Competitors 28
RaQualia Pharma Inc, Key Employees 29
RaQualia Pharma Inc, Other Locations 30
RaQualia Pharma Inc, Subsidiaries 30

List of Figures
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
RaQualia Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
RaQualia Pharma Inc, Medical Devices Deals, 2012 to YTD 2018 9

★調査レポート[RaQualia Pharma Inc (4579):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C8096)販売に関する免責事項を必ずご確認ください。
★調査レポート[RaQualia Pharma Inc (4579):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆